header image

News

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A

18.06.2018

Lachen, Switzerland 18 June 2018: Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII)...

Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018

28.05.2018

Lachen, Switzerland 28 May 2018: Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8,...

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress

28.05.2018

Lachen, Switzerland 28 May 2018: Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World...

Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million

01.03.2018

Lachen, Switzerland, March 1st, 2018: Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017, with sales of €1.72 billion...

Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

22.01.2018

Lachen, Switzerland, January 22nd, 2018: Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia. The study...